Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; DeTIL-0255 for tumor infiltrating lymphocytes therapy; KINASE-CTM3 to treat T cell malignancies and autoimmune diseases; and LIGASE-INH2 for immuno-oncology. In addition, the company develops programs, such as COVID-CTM1, COVID-CTM2, and COVID-CTM3 that are designed for protein degradation to SARs CoV2 targets. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
IPO Year: 2020
Exchange: NASDAQ
Website: nurixtx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2026 | $36.00 | Equal-Weight → Overweight | Morgan Stanley |
| 11/24/2025 | $30.00 | Buy | Truist |
| 10/21/2025 | $24.00 | Outperform | Mizuho |
| 3/17/2025 | $16.00 | Market Perform | Leerink Partners |
| 12/10/2024 | $35.00 | Buy | BTIG Research |
| 12/6/2024 | $35.00 | Outperform | BMO Capital Markets |
| 10/24/2024 | $35.00 | Buy | UBS |
| 10/11/2024 | $41.00 | Buy | Jefferies |
| 9/6/2024 | $26.00 | Outperform | Robert W. Baird |
| 7/31/2024 | $36.00 | Buy | Truist |
8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
SCHEDULE 13G - Nurix Therapeutics, Inc. (0001549595) (Subject)
SCHEDULE 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
10-Q - Nurix Therapeutics, Inc. (0001549595) (Filer)
8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
SCHEDULE 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
DEF 14A - Nurix Therapeutics, Inc. (0001549595) (Filer)
DEFA14A - Nurix Therapeutics, Inc. (0001549595) (Filer)
8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
424B5 - Nurix Therapeutics, Inc. (0001549595) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Fastest customizable press release news feed in the world
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
Morgan Stanley upgraded Nurix Therapeutics from Equal-Weight to Overweight and set a new price target of $36.00
Truist resumed coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $30.00
Mizuho initiated coverage of Nurix Therapeutics with a rating of Outperform and set a new price target of $24.00
Leerink Partners initiated coverage of Nurix Therapeutics with a rating of Market Perform and set a new price target of $16.00
BTIG Research initiated coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $35.00
BMO Capital Markets initiated coverage of Nurix Therapeutics with a rating of Outperform and set a new price target of $35.00
UBS initiated coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $35.00
Jefferies initiated coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $41.00
Robert W. Baird resumed coverage of Nurix Therapeutics with a rating of Outperform and set a new price target of $26.00
Truist initiated coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $36.00
In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of FcεRI-driven pathology versus remibrutinib In healthy volunteers, both single- and multiple-ascending-dose oral dosing of bexobrutideg led to rapid and robust BTK degradation in blood and skin Phase 1 studies support continued exploration of new tablet formulation in inflammation and immunology indications BRISBANE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the
BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in fireside chats at the following investor conferences: RBC Global Healthcare ConferenceWednesday, May 20, 2026, at 1:30 p.m. ET. Jefferies Global Healthcare ConferenceWednesday, June 3, 2026, at 11:05 a.m. ET. The fireside chats will be webcast live and may be viewed via a link in the Investors section
BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that an abstract highlighting updated efficacy and safety data from the ongoing Phase 1a/b trial of BTK degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL) across lines of therapy has been accepted for oral presentation at the 31st Congress of the European Hematology Association (EHA2026), taking place June 11-14, 2026, in Stockholm, Sweden. Oral Presentation Details: Title: Updated efficacy and safety data
Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs Presentations reinforce potential of degraders to overcome limitations of inhibitors and expand therapeutic reach Featured AACR Advances session underscores Nurix's scientific leadership in targeted protein degradation and induced proximity pharmacology BRISBANE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation therapies, today announced new preclinical data from multiple oncology programs at the American Association for Cancer Research (AACR) Annual Meeting 2026. The pres
Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg confirmatory trial for full approval in r/r CLL Targeting 2026 IND submission for bexobrutideg in inflammatory and autoimmune indications with a new tablet formulation Continuing advancement of targeted protein degraders of IRAK4 in Phase 1 and STAT6 in IND-enabling studies under strategic partnerships Well capitalized with $540.7 million on the balance sheet BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical
BRISBANE, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference in April. Needham Virtual Healthcare ConferenceArthur T. Sands, M.D., Ph.D., president and chief executive officer of NurixMonday, April 13, 2026, at 1:30 – 2:10 p.m. ET The fireside chat will be webcast live and may be viewed via a link in the Investors section of th
BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that two oral presentations and three poster presentations highlighting the breadth of its research pipeline and scientific leadership will be presented at the American Association for Cancer Research (AACR) 2026 Annual Meeting, to be held April 17-22, 2026, in San Diego, California. The presentations will provide additional mechanistic validation of CBL-B, Aurora kinase A (AURKA) and mutant BRAF as therapeutic targets across multiple can
First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile in relapsed/refractory CLL 83% objective overall response rate and progression free survival of 22.1 months demonstrate durable therapeutic effects in a large portion of patients Presented differentiated preclinical data for IRAK4 degrader GS-6791 in collaboration with Gilead Well capitalized with cash and marketable securities of $592.9 million BRISBANE, Australia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical compan
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Jan. 14, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The precision oncology market is hitting a massive growth spurt, projected to rocket from $110 billion toward a staggering $225.65 billion by 2032[1]. This gold rush is accelerating as Big Pharma giants scramble to survive a looming $170 billion patent cliff that threatens to vaporize blockbuster revenues through 2030[2]. This high-stakes hunt for registration-ready assets is driving the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), Nurix Therapeutics (NASDAQ:NRIX), Erasca (NASDAQ:ERAS), Foghorn Therapeutics (NASDAQ:FHTX), and ORIC Pharmaceuticals (N
Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Expand bexobrutideg into autoimmune and inflammatory indications, targeting IND submission in 2026 with a new tablet formulation Advance a growing portfolio of partnered inflammation and immunology programs, including potent and selective degraders of IRAK4 and STAT6 Leverage DEL-AI platform to drive discovery against high-value targets across internal and partnered programs BRISBANE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX
This live feed shows all institutional transactions in real time.
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
Live Leadership Updates
SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, who previously served as Chief Development Officer and Chief Oncology Officer of Pfizer Oncology and as Chief Medical Officer and interim Chief Executive Officer of Seagen Inc., has had a distinguished career in hematology and oncology and over two decades of leadership experience in drug development and commercialization. "Roger
NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M license extension fee from ongoing collaboration with SanofiEnhanced oversight and leadership team with the appointments of Roy D. Baynes to the Board and John Northcott as chief commercial officerWell capitalized with cash and marketable securities of $549.7 million SAN FRANCISCO, April 08, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medi
SAN FRANCISCO, March 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, announced today the appointment of Roy D. Baynes, MB.Bch., M.Med., Ph.D., to its board of directors. Dr. Baynes, who currently serves as executive vice president and chief medical officer of Eikon Therapeutics, has had a distinguished career in hematology and oncology and over 22 years of clinical leadership experience in pharmaceutical and biotech companies. "Roy has been a trusted advisor to Nurix since 2023, and I am delighted to welcome him to our board
Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th American Society of Hematology Annual Meeting Received PRIME designation from the European Medicines Agency for NX-5948 in CLL Received Fast Track designation from the U.S. FDA for NX-5948 in Waldenstrom's Macroglobulinemia Announced the appointment of John Northcott as Chief Commercial Officer Well capitalized with cash and marketable securities of $609.6 million SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercial
SAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of John Northcott as chief commercial officer (CCO). Mr. Northcott has over 20 years of commercial experience, including as CCO for several biotechnology companies building commercial organizations and successfully commercializing the first marketed BTK inhibitor ibrutinib. "We are thrilled to have John join the Nurix team as we prepare to launch our pivotal clinical program for NX-5948 in chronic lymphocytic leukemia
SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of Anil Kapur to its board of directors, effective October 15, 2024. Mr. Kapur has over 25 years of executive experience in pharmaceutical and biotech companies across both U.S. and international markets. "I am delighted to welcome Anil to the Nurix board as we enter this important stage in the company's development and execute on our plan to advance NX-5948 into pivotal clinical testing in 2025 and prepare for future
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointments of Paula G. O'Connor, M.D., as chief medical officer and Pasit Phiasivongsa, Ph.D., as chief technical officer of Nurix. "I am delighted to announce the promotions of both Paula and Pasit, which recognize their significant and ongoing leadership in advancing our pipeline of novel medicines and particularly in accelerating our NX-5948 program in chronic lymphocytic leukemia and non-Hodgkin's lymphoma," said Arthur T. Sa
Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its DELigase platform Clinical data updates planned for Nurix's two first-in-class BTK degraders in 2023 Clinical data update planned for Nurix's first-in-class CBL-B inhibitor in 2023 Significant progress made across deep pipeline of preclinical candidates SAN FRANCISCO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today outlined key objectives and anticipated mil
Completed two registered direct offerings in July raising gross proceeds of $95 million Maintained strong financial position with $413.6 million in cash and marketable securities as of August 31, 2022 Expanded leadership team and board of directors with experienced industry leaders Announced multiple presentations at upcoming SITC 2022 annual meeting, including initial PK/PD data for NX-1607 program SAN FRANCISCO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the third quarter ended August 31, 2022 and provided a corporate update. "
SAN FRANCISCO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Edward C. Saltzman to its board of directors. Mr. Saltzman has over 30 years of drug strategic development experience in the biopharmaceutical and biotechnology industries, and currently serves as Head of Biotech Strategy at Lumanity Inc., a global pharmaceutical and biotechnology advisory firm. "I am delighted to welcome Ed to the Nurix board of directors at this important stage in the Company's growth as we advance multiple programs through clinical trials with significant p
Live finance-specific insights
600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated for potential Accelerated Approval New preclinical data support bexobrutideg as potential best-in-class BTK degrader profile Nurix will host an investor webcast today, Wednesday, October 22nd, at 8:00 a.m. EDT SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced t
Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM Bexobrutideg was well tolerated with no new safety signals observed with longer duration on study or higher doses Data reinforces Nurix's scientific leadership and platform strength in targeted protein degradation Nurix remains on track to initiate pivotal trials of bexobrutideg in 2025 Data are being presented at the 30th European Hematology Association Congress (EHA2025) Company will host a webcast conference call today, June 12, 2025, at 8:00 a.m. ET (2:00 p.m. CEST) SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clin
SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that the company will host a webcast conference call at 8:00 a.m., ET, on Thursday, June 12, 2025, to discuss new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) that will be presented at the European Hematology Association Congress in Milan, Italy. Details of the webcast and conference call are as follows: Date and time: Thursday, June 12, 8:00 a.m. ET / 2:00 p.m. CEST Access details: The live webcast will be a
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and deepening with longer time on treatment Nurix intends to advance NX-5948 into pivotal trial(s) in 2025 Company will host a webcast conference today, June 16, 2024, at 9:00 a.m. ET (3:00 p.m. CEST) SAN FRANCISCO, June 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the presentation of updated clinical d
SAN FRANCISCO, June 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the company will host a webcast and conference call at 9:00 a.m., ET, on Sunday, June 16, 2024, to discuss data from the ongoing Phase 1 clinical trial of NX-5948 that will be presented in an oral session at the European Hematology Association Congress in Madrid, Spain. The oral presentation at EHA2024 will summarize updated data from the ongoing Phase 1a/b study of NX-5948 in heavily pretreated patients with relapsed/refractor
Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time on therapy in CLL patients including patients with resistance mutations to BTK inhibitors The oral presentation at EHA will include additional data at higher dose levels and longer treatment durations Company will host a webcast conference call on June 16 following the data presentation at EHA (details to follow) SAN FRANCISCO, May 14, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory
Nurix and Seagen to develop a portfolio of Degrader-Antibody Conjugates (DACs): antibodies that deliver a targeted protein degrader payload to selectively kill cancer cells Nurix to receive a $60 million upfront payment, in addition to the potential for approximately $3.4 billion in milestone payments plus future royalties Nurix retains an option for U.S. profit sharing and co-promotion on two products arising from the collaboration Nurix to host a conference call today, September 7 at 8:30 a.m. ET SAN FRANCISCO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to
Robust BTK target degradation achieved in all patients treated to date Greater than 90% degradation of BTK was achieved at the 200 mg dose of NX-2127 These data represent the first proof of mechanism of targeted protein degradation in patients with hematologic malignancies Nurix to host a conference call today at 8:30 a.m. ET SAN FRANCISCO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced initial data demonstrating clinically meaningful degradation of Bruton's tyrosine kinase (BTK) in patients with relapsed or refractory B cell malignancies, including in a chronic lympho
Presentation to include initial pharmacokinetic and BTK degradation data Company to host conference call at 8:30 a.m. ET on Wednesday, October 27, 2021 SAN FRANCISCO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that the Company will present initial pharmacokinetic and pharmacodynamic data from its first-in-human, Phase 1 dose-escalation trial of NX-2127 in adults with relapsed or refractory B-cell malignancies at the 4th Annual Targeted Protein Degradation Summit. The presentation will begin at 11:45 a.m. ET on Wednesday, October 27, 2021, and will be given by Nurix pr